Nectar Lifesciences Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Nectar Lifesciences.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.4%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive

Oct 11

Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Aug 22

Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Jul 27

Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Feb 19

If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

Aug 09

The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

Aug 09

What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Jul 13

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Nectar Lifesciences no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:NECLIFE - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	16,493	61	N/A	N/A	N/A
3/31/2024	16,846	50	1,953	2,247	N/A
12/31/2023	16,322	81	N/A	N/A	N/A
9/30/2023	15,241	-28	1,473	1,765	N/A
6/30/2023	15,148	-263	N/A	N/A	N/A
3/31/2023	15,237	-242	1,036	1,337	N/A
12/31/2022	16,120	-162	N/A	N/A	N/A
9/30/2022	17,109	28	1,459	1,708	N/A
6/30/2022	16,868	272	N/A	N/A	N/A
3/31/2022	16,689	250	700	950	N/A
12/31/2021	15,421	-276	N/A	N/A	N/A
9/30/2021	14,765	-454	435	790	N/A
6/30/2021	15,387	-546	N/A	N/A	N/A
3/31/2021	15,433	-733	-99	214	N/A
12/31/2020	17,586	-249	N/A	N/A	N/A
9/30/2020	20,291	-86	903	1,399	N/A
6/30/2020	21,807	12	N/A	N/A	N/A
3/31/2020	23,664	318	2,302	2,850	N/A
12/31/2019	25,973	419	N/A	N/A	N/A
9/30/2019	26,819	446	2,339	2,632	N/A
6/30/2019	28,274	480	N/A	N/A	N/A
3/31/2019	27,829	476	2,011	2,392	N/A
3/31/2018	18,763	523	N/A	652	N/A
3/31/2017	16,437	553	N/A	1,988	N/A
3/31/2016	16,757	542	N/A	1,688	N/A
3/31/2015	16,436	663	N/A	1,444	N/A
3/31/2014	16,383	621	N/A	2,549	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if NECLIFE's forecast earnings growth is above the savings rate (6.7%).

Beneficios vs. Mercado: Insufficient data to determine if NECLIFE's earnings are forecast to grow faster than the Indian market

Beneficios de alto crecimiento: Insufficient data to determine if NECLIFE's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if NECLIFE's revenue is forecast to grow faster than the Indian market.

Ingresos de alto crecimiento: Insufficient data to determine if NECLIFE's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if NECLIFE's Return on Equity is forecast to be high in 3 years time

Nectar Lifesciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Nectar Lifesciences Limited to Report Q2, 2025 Results on Nov 14, 2024

Nectar Lifesciences Limited Provides Update on Details of Litigation Orders Passed Principal Commissioner of Income Tax (Central), Gurugram

New minor risk - Market cap size

Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive

Nectar Lifesciences Limited Provides Update on Details of Litigation And/ or Orders Passed by Any Regulatory Authority or Judicial Body

New minor risk - Share price stability

Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

First quarter 2025 earnings released: EPS: ₹0.13 (vs ₹0.08 in 1Q 2024)

Nectar Lifesciences Limited, Annual General Meeting, Sep 21, 2024

Nectar Lifesciences Limited to Report Q1, 2025 Results on Aug 14, 2024

Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Nectar Lifesciences Limited to Report Fiscal Year 2024 Results on May 15, 2024

Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

New minor risk - Share price stability

Third quarter 2024 earnings released: EPS: ₹0.07 (vs ₹0.41 loss in 3Q 2023)

Nectar Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Second quarter 2024 earnings released: EPS: ₹0.05 (vs ₹1.00 loss in 2Q 2023)

Nectar Lifesciences Limited to Report Q2, 2024 Results on Nov 10, 2023

New minor risk - Share price stability

Full year 2023 earnings released: ₹1.08 loss per share (vs ₹1.12 profit in FY 2022)

Nectar Lifesciences Limited to Report Q1, 2024 Results on Aug 14, 2023

New minor risk - Share price stability

Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: ₹1.08 loss per share (vs ₹1.12 profit in FY 2022)

Nectar Lifesciences Limited, Annual General Meeting, Sep 21, 2023

Nectar Lifesciences Limited to Report Fiscal Year 2023 Results on May 26, 2023

Nectar Lifesciences Limited Appoints Neha Vaishnav as the Company Secretary

Third quarter 2023 earnings released: ₹0.41 loss per share (vs ₹0.43 profit in 3Q 2022)

Nectar Lifesciences Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: ₹1.00 loss per share (vs ₹0.08 profit in 2Q 2022)

Nectar Lifesciences Limited Announces Executive Changes

Nectar Lifesciences Limited to Report Q2, 2023 Results on Nov 14, 2022

Nectar Lifesciences Limited Appoints Puneet Sud as Additional Director on the Board

Nectar Lifesciences Limited Announces Resignation of Director, Sanjit Singh Lamba

First quarter 2023 earnings released: EPS: ₹0.17 (vs ₹0.08 in 1Q 2022)

Nectar Lifesciences Limited Appoints Indu Pal Kaur as an Independent (Woman) Director

Nectar Lifesciences Limited Announces Resignation of Dinesh Dua as an Executive Director as Well as Director, Effective July 09, 2022

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Full year 2022 earnings released: EPS: ₹1.12 (vs ₹3.27 loss in FY 2021)

Nectar Lifesciences Limited, Annual General Meeting, Sep 21, 2022

Nectar Lifesciences Limited to Report Fiscal Year 2022 Results on May 30, 2022

Nectar Lifesciences Limited Announces Resignation of Guljit Sethi as Board Member, Effective May 09, 2022

Nectar Lifesciences Limited Announces Resignation of Vivek Sett as Director

Now 20% undervalued after recent price drop

Now 20% undervalued

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Nectar Lifesciences Limited to Report Q3, 2022 Results on Feb 14, 2022

Second quarter 2022 earnings released: EPS ₹0.08 (vs ₹0.33 loss in 2Q 2021)

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Full year 2021 earnings released: ₹3.27 loss per share (vs ₹1.42 profit in FY 2020)

Additional Independent Director Ajit Dhillon has left the company

Company Secretary & Compliance Officer Sukriti Saini has left the company

Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Nectar Lifesciences Limited Appoints Ajit Singh Dhillon as Additional Director

Third quarter 2021 earnings released: ₹0.36 loss per share (vs ₹0.37 profit in 3Q 2020)

Nectar Lifesciences Limited to Report Q3, 2021 Results on Feb 13, 2021

Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

New 90-day high: ₹23.80

Nectar Lifesciences Limited Announces Demise of Dr. (Maj Gen.) S.S. Chauhan, Independent Director

Second quarter 2021 earnings released: ₹0.33 loss per share

Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Nectar Lifesciences Limited Appoints Amit Chadah as Chief Executive Officer

New 90-day low: ₹19.80

First quarter earnings released

Nectar Lifesciences Limited to Report Q1, 2021 Results on Oct 01, 2020

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Upcoming Dividend of ₹0.05 Per Share

Earnings released

If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción